Publications by authors named "T M Al Quran"

Background: Despite the advantages of vaccination in preventing maternal and fetal problems, there were many concerns in the medical community regarding vaccine safety for pregnant women, and this has put obstetricians in a challenging situation when it comes to advising their pregnant patients on whether to obtain the vaccine.

Aim: This study was performed to define the level of acceptance of COVID-19 vaccination and assess the impact of COVID-19 attitudes and knowledge on vaccine acceptance between pregnant and lactating Syrian women who are seeking prenatal care services at the clinics in Azraq refugee camp in Jordan.

Method: A quantitative, cross-sectional study utilizing a non-probability convenience sample.

View Article and Find Full Text PDF

Background: Several studies documented that metformin use contributes to vitamin B12 deficiency in patients with type 2 diabetes mellitus (T2DM). However, there has been a lack of data assessing this issue in Jordan.

Aims: Assess the vitamin B12 serum levels, frequency of vitamin B12 deficiency, and related factors among Jordanian patients with T2DM patients treated with metformin.

View Article and Find Full Text PDF
Article Synopsis
  • * The study identified low levels of HDL-C (66.2%), high levels of LDL-C (62.1%), and elevated triglycerides (58.2%) as the most common dyslipidemia patterns among the patients.
  • * Factors like female gender, obesity, hypertension, and poor glycemic control were linked to these dyslipidemia patterns, emphasizing the need for targeted interventions to manage these issues effectively.
View Article and Find Full Text PDF

Introduction: Pembrolizumab has been on the market for several years, but most of the safety data is based on clinical trials with limited literature evaluating post-marketing immune-related adverse events (irAEs) associated with its use. This study aimed to evaluate the characteristics of irAEs associated with pembrolizumab.

Methods: We included adult patients who had received pembrolizumab between January 2016 and December 2020.

View Article and Find Full Text PDF